​

Lunai Bioworks Stock (NASDAQ:LNAI)

FinancialsChart
Lunai Bioworks by TradingView

Previous Close

$3.09

52W Range

$1.21 - $28.80

50D Avg

$2.74

200D Avg

$5.95

Market Cap

$14.51M

Avg Vol (3M)

$1.56M

Beta

0.35

Div Yield

-

LNAI Company Profile

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Sep 30, 2025

Website

LNAI Performance

LNAI Financial Summary

Jun 25Jun 24Jun 23
Revenue---
Operating Income$-188.97M$-81.64M$-38.56M
Net Income$-178.01M$-88.43M$-39.68M
EBITDA$-177.15M$-85.87M$-38.86M
Basic EPS-$-9.10$-7.10
Diluted EPS-$-9.10$-7.10

Fiscal year ends in Jun 25 | Currency in USD

Peer Comparison

TickerCompany
ERNAErnexa Therapeutics Inc.
MBRXMoleculin Biotech, Inc.
BLRXBioLineRx Ltd.
ADAPAdaptimmune Therapeutics plc
ICUSeaStar Medical Holding Corporation
GOVXGeoVax Labs, Inc.
APLMApollomics, Inc.
LPCNLipocine Inc.
THARTharimmune, Inc.
ANLAdlai Nortye Ltd.